title: A protective effect of 5-HT3 antagonist against vestibular deficit? Metoclopramide versus ondansetron at the early stage of vestibular neuritis: a pilot study.
abstract: OBJECTIVE
  Ondansetron is an antiemetic 5-HT3 receptor antagonist with proven efficacy in central balance disorder. A pilot study investigated impact on acute unilateral vestibular neuritis.
  
  
  METHODS
  A randomized clinical trial included 20 vestibular neuritis patients. Subjects received methylprednisolone-valacyclovir, associated to 5 days' metoclopramide (30 mg/d; group M, n=10) or ondansetron (8 mg/d; group O, n=10). Assessment was based on early and 1 month videonystagmography, duration of hospital stay and time to first independent walking. Blinded intention-to-treat analysis used univariate (Student test) and multivariate (linear logistic regression) analysis.
  
  
  RESULTS
  Early caloric vestibular deficit was significantly lower in group O than group M (56.53% versus 84.38%; P=0.03). Vestibular preponderance did not differ between groups (8.2°/s in O versus 10.34°/s in M). At 1 month, trends were observed for vestibular deficit (43% in O versus 63.4% in M; P=0.07) and preponderance (1.67°/s in O versus 1.74°/s in M; P=0.4). Hospital stay and time to first independent walking were significantly shorter in O (2.88 versus 4.5 days (P=0.03); and 1.25 versus 2.25 days (P=0.001), respectively).
  
  
  CONCLUSIONS
  Early treatment with ondansetron associated to corticosteroids and antiviral treatment reduced vestibular deficit in acute-phase vestibular neuritis as compared to reference histamine H1 receptor antagonists. The treatment did not affect central compensation. Benefit includes improved tolerance of vertigo syndrome and reduced hospital stay. These results should be confirmed on a larger series, particularly to determine the mechanism of action of 5-HT3 antagonists on vestibular function.
authors.affiliation: Service ORL, département otologie et otoneurologie, hôpital Gui-de-Chauliac, CHRU, 80 avenue Augustin-Fliche, Montpellier cedex 5, France. frederic.venail@inserm.fr
authors.forename: F
authors.initials: F
authors.lastname: Venail
authors.forename: R
authors.initials: R
authors.lastname: Biboulet
authors.forename: M
authors.initials: M
authors.lastname: Mondain
authors.forename: A
authors.initials: A
authors.lastname: Uziel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000932:Antiemetics / Q000627:therapeutic use*; D006801:Humans; D008787:Metoclopramide / Q000627:therapeutic use*; D008875:Middle Aged; D017294:Ondansetron / Q000627:therapeutic use*; D010865:Pilot Projects; D058831:Serotonin 5-HT3 Receptor Antagonists / Q000627:therapeutic use*; D014724:Vestibular Function Tests; D020338:Vestibular Neuronitis / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000932:Antiemetics; D058831:Serotonin 5-HT3 Receptor Antagonists; D017294:Ondansetron; D008787:Metoclopramide